Unlock this StockReport nowClick to Unlock

21st North Inc

ULGX $0.004 -0.0  -18.0%
8:07pm

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary

FINANCIAL BRIEF: For the nine months ended 31 March 2015, 21st North Inc revenues decreased 19% to $8.9M. Net loss decreased 72% to $1.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Sales and marketing decrease of 86% to $651K (expense), General & Admiistrative decrease of 74% to $441K (expense), Other Reaserch and Development decrease of 76% to $297K (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score  
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 31st Mar '15) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
30th Jun 2015
30th Jun 2016

Price Target: N/A
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a ($) ($) ($) ($) ($) ($)
Consensus Estimate
1m Change
3m Change
Broker Consensus Trend
Broker Recommendations for 21st North Inc
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
Dougherty & Company LLC ,

Profile Summary

21st North Inc., formerly Urologix Inc., was engaged in developing, manufacturing, marketing and distributing medical products. The Company offered its products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The Company has no operations. The Company intends to dissolve.

Directors: Gregory Fluet (CEO) 45, Scott Madson (CFO) 51, Lisa Ackermann (EVP) 42, Mitchell Dann (NEC) 55, Christopher Barys (IND) 48, Sidney Emery (IND) 71, Patrick Spangler (IND) 60,

No. of Employees: 61 No. of Shareholders: n/a


Last Annual June 30th, 2014
Last Interim March 31st, 2015
Incorporated May 29, 1991
Public Since May 30, 1996
Shares in Issue 21,817,726
Free Float 21.8m (100.0%)
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange OTC Markets Group
Eligible for an ISA? a SIPP?

ULGX Share Price Performance ULGXQuote
$0.004
-0.0  -18.0%
Traded 8:07pm · Minimum 15 min delayed · NMS:

Latest ULGX News Announcements (delayed)

Upcoming ULGX Events

Recent ↓
Friday 6th November, 2015 (estimate)
Urologix Inc Annual Shareholders Meeting
Thursday 20th August, 2015 (estimate)
Q4 2015 Urologix Inc Earnings Release
Tuesday 12th May, 2015
Q3 2015 Urologix Inc Earnings Call
Tuesday 12th May, 2015
Q3 2015 Urologix Inc Earnings Release
Thursday 5th February, 2015
Q2 2015 Urologix Inc Earnings Call
Thursday 5th February, 2015
Q2 2015 Urologix Inc Earnings Release
Monday 12th January, 2015
Preliminary Q2 2015 Urologix Inc Earnings Release
Thursday 6th November, 2014
Urologix Inc Annual Shareholders Meeting
Tuesday 4th November, 2014
Q1 2015 Urologix Inc Earnings Call
Tuesday 4th November, 2014
Q1 2015 Urologix Inc Earnings Release
Tuesday 19th August, 2014
Q4 2014 Urologix Inc Earnings Call
Tuesday 19th August, 2014
Q4 2014 Urologix Inc Earnings Release
Tuesday 6th May, 2014
Q3 2014 Urologix, Inc. Earnings Conference Call
Tuesday 6th May, 2014
Q3 2014 Urologix, Inc. Earnings Release


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2018.


Should you buy ULGX

Access ULGX Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis